These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37924972)

  • 1. MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC.
    Haratake N; Ozawa H; Morimoto Y; Yamashita N; Daimon T; Bhattacharya A; Wang K; Nakashoji A; Isozaki H; Shimokawa M; Kikutake C; Suyama M; Hashinokuchi A; Takada K; Takenaka T; Yoshizumi T; Mitsudomi T; Hata AN; Kufe D
    J Thorac Oncol; 2024 Mar; 19(3):434-450. PubMed ID: 37924972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NUAK1-Mediated Phosphorylation of NADK Mitigates ROS Accumulation to Promote Osimertinib Resistance in Non-Small Cell Lung Carcinoma.
    Lin W; Wang N; Wu S; Diao M; Huang Q; Li K; Mei P; Wang X; Liao Y; Meng Y
    Cancer Res; 2024 Dec; 84(23):4081-4098. PubMed ID: 39159134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac Events and Survival in Patients With EGFR-Mutant Non-Small Cell Lung Cancer Treated With Osimertinib.
    Lin CY; Chang WT; Su PL; Kuo CW; Yang J; Lin CC; Lin SH
    JAMA Netw Open; 2024 Dec; 7(12):e2448364. PubMed ID: 39636639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting.
    Kraskowski O; Stratmann JA; Wiesweg M; Eberhardt W; Metzenmacher M; Schmid KW; Herold T; Schildhaus HU; Darwiche K; Aigner C; Stuschke M; Laue K; Zaun G; Kasper S; Hense J; Sebastian M; Schuler M; Pogorzelski M
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):9243-9252. PubMed ID: 37198447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antitumor activity of osimertinib plus palbociclib in non-small cell lung cancer patient-derived xenograft (PDX)/2D/3D culture models harboring EGFR amplification and CDKN2A/2B homozygous deletions.
    Fu JF; Hsu CL; Hsu PC
    Neoplasia; 2024 Nov; 57():101039. PubMed ID: 39146623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study.
    Lu S; Ahn MJ; Reungwetwattana T; Özgüroğlu M; Kato T; Yang JC; Huang M; Fujiki F; Inoue T; Quang LV; Sriuranpong V; Vicente D; Fuentes C; Chaudhry AA; Poole L; Armenteros Monterroso E; Rukazenkov Y; van der Gronde T; Ramalingam SS
    Ann Oncol; 2024 Dec; 35(12):1116-1125. PubMed ID: 39289145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of First-Line Osimertinib and Other EGFR-Tyrosine Kinase Inhibitors on Overall Survival in Untreated Advanced EGFR-Mutated Non-small Cell Lung Cancer in Japan: Updated Data from TREAD Project 01.
    Hibino M; Imamura Y; Shimoyama R; Fukui T; Fukai R; Iwase A; Tamura Y; Chihara Y; Okabe T; Uryu K; Okuda T; Taguri M; Minami H
    Target Oncol; 2024 Nov; 19(6):925-939. PubMed ID: 39302602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting C797S mutations and beyond in non-small cell lung cancer-a mini-review.
    Dempke WCM; Fenchel K
    Transl Cancer Res; 2024 Nov; 13(11):6540-6549. PubMed ID: 39697713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integration of osimertinib-targeted EGFR gene-associated differential gene expression in constructing a prognostic model for lung adenocarcinoma.
    Li H; Yang L; Yang Q; Liang Z; Su W; Yu L
    Funct Integr Genomics; 2024 Dec; 24(6):226. PubMed ID: 39661202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, Synthesis, and Biological Evaluation of Novel Diaminopyrimidine Macrocycles as Fourth Generation Reversible EGFR Inhibitors That Overcome Clinical Resistance to Osimertinib Mediated by C797S Mutation.
    Hu S; Tong L; Qin Q; Wen J; Li Y; Feng F; Wu K; Zhou Y; Shang J; Wang J; Liu J; Xie H; Lu X
    J Med Chem; 2024 Nov; 67(22):20531-20558. PubMed ID: 39536262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Osimertinib in Patients With Non-Small-Cell Lung Cancer and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and Single-Arm Meta-Analysis.
    Priantti JN; Fujiwara Y; Aquino de Moraes FC; Michelon I; Castro C; Leighl NB; Cavalcante L; Addeo A; Bar J; Horita N; Cortellini A; Nassar AH; Vilbert M; Naqash AR
    JCO Precis Oncol; 2024 Nov; 8():e2400331. PubMed ID: 39576954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome-wide CRISPR screens identify the YAP/TEAD axis as a driver of persister cells in EGFR mutant lung cancer.
    Pfeifer M; Brammeld JS; Price S; Pilling J; Bhavsar D; Farcas A; Bateson J; Sundarrajan A; Miragaia RJ; Guan N; Arnold S; Tariq L; Grondine M; Talbot S; Guerriero ML; O'Neill DJ; Young J; Company C; Dunn S; Thorpe H; Martin MJ; Maratea K; Barrell D; Ahdesmaki M; Mettetal JT; ; Brownell J; McDermott U
    Commun Biol; 2024 Apr; 7(1):497. PubMed ID: 38658677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Difference in efficacy of osimertinib between patients with EGFR-positive NSCLC with postoperative recurrence and those with de novo unresectable disease: A prospective, observational study.
    Karayama M; Suda T; Yoh K; Usui K; Hosomi Y; Kishi K; Naka G; Watanabe K; Tamano S; Uemura K; Kunitoh H
    Lung Cancer; 2024 Dec; 198():108037. PubMed ID: 39602849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What is the optimal first-line regimen for advanced non-small cell lung cancer patients with epidermal growth factor receptor mutation: a systematic review and network meta-analysis.
    Zhang W; Zhang X; Zhao W; Guo Z; Liu X; Ye L; Chen Z; Xu K; Liu Y; Wang H; Zhao L; Zhang Q; Li Y; Chen X; He Y
    BMC Pulm Med; 2024 Dec; 24(1):620. PubMed ID: 39695621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exposure-response modelling of osimertinib in patients with non-small cell lung cancer.
    Johnson M; Lin YW; Schmidt H; Sunnaker M; Van Maanen E; Huang X; Rukazenkov Y; Tomkinson H; Vishwanathan K
    Br J Clin Pharmacol; 2024 Dec; 90(12):3263-3276. PubMed ID: 39160062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined analysis of circulating tumor DNA and tumor tissue to overcome osimertinib resistance (OSIRIS); the second line osimertinib cohort.
    van der Wel JWT; Jebbink M; van den Broek D; Steinbusch LC; Theelen WSME; Ruiter G; Buikhuisen W; Burgers JA; Baas P; Vermeulen M; van der Noort V; Hashemi SMS; Bosch LJW; Monkhorst K; Smit EF; Boelens MC; de Langen AJ
    Lung Cancer; 2024 Dec; 198():107972. PubMed ID: 39556978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma-Based Comprehensive Genomic Profiling DNA Assays for Non-Small Cell Lung Cancer: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2024; 24(8):1-306. PubMed ID: 39698418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effectiveness of abstinence-based and harm reduction-based interventions in reducing problematic substance use in adults who are experiencing homelessness in high income countries: A systematic review and meta-analysis: A systematic review.
    O'Leary C; Ralphs R; Stevenson J; Smith A; Harrison J; Kiss Z; Armitage H
    Campbell Syst Rev; 2024 Jun; 20(2):e1396. PubMed ID: 38645303
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.